Comment on

• Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.

  Shi Y, Li Y, Tang J, Zhang J, Zou Y, Cai B, Wang L. Shi Y, et al. Gene. 2013 Jan 10;512(2):226-31. doi: 10.1016/j.gene.2012.10.048. Epub 2012 Oct 26. Gene. 2013. PMID: 23107770
• Increased hospital stay and allograft dysfunction in renal transplant recipients with Cyp2c19 AA variant in SNP rs4244285.

  Bosó V, Herrero MJ, Bea S, Galiana M, Marrero P, Marqués MR, Hernández J, Sánchez-Plumed J, Poveda JL, Aliño SF. Bosó V, et al. Drug Metab Dispos. 2013 Feb;41(2):480-7. doi: 10.1124/dmd.112.047977. Epub 2012 Nov 21. Drug Metab Dispos. 2013. PMID: 23175667
• Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation.

  Chakkera HA, Chang YH, Bodner JK, Behmen S, Heilman RL, Reddy KS, Mulligan DC, Moss AA, Khamash H, Katariya N, Hewitt WR, Pitta TL, Frassetto LA. Chakkera HA, et al. Transplant Proc. 2013 Jan-Feb;45(1):137-41. doi: 10.1016/j.transproceed.2012.10.023. Transplant Proc. 2013. PMID: 23375287
• Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.

  Zuo XC, Ng CM, Barrett JS, Luo AJ, Zhang BK, Deng CH, Xi LY, Cheng K, Ming YZ, Yang GP, Pei Q, Zhu LJ, Yuan H, Liao HQ, Ding JJ, Wu D, Zhou YN, Jing NN, Huang ZJ. Zuo XC, et al. Pharmacogenet Genomics. 2013 May;23(5):251-61. doi: 10.1097/FPC.0b013e32835fcbb6. Pharmacogenet Genomics. 2013. PMID: 23459029